Drugs / Human Serum Albumin/interferon alpha2b fusion protein
Human Serum Albumin/interferon alpha2b fusion protein
Trials 1 · a red edge is where a trial was stopped
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1/2 | NCT03294798 | Jun 2017 → Mar 2019 | hepatitis B virus infection | Tianjin SinoBiotech Ltd. | Completed | No outcome recorded |
Evidence & citations 2 cited values
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | Human Serum Albumin/interferon alpha2b fusion protein | ClinicalTrials.gov intervention name — accepted as the source's own label NCT03294798 ↗ |
| Modality | Protein / enzyme biologic | “Human Serum Albumin/interferon alpha2b Fusion Protein” NCT03294798 ↗ |